Blog
RSS FeedPosted by Michael Wonder on 03 Feb 2019
Erenumab in migraine: indication of a significant added benefit for certain patients
2 February 2019 - As a prophylaxis successful when other drug therapies are exhausted. ...
Posted by Michael Wonder on 29 Jan 2019
Identifying the need for good practices in health technology assessment-summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA
26 January 2019 - The systematic use of evidence to inform healthcare decisions, particularly health technology assessment, has gained increased recognition. ...
Posted by Michael Wonder on 23 Jan 2019
Citizens ask - scientists answer: the IQWiG sets four new topics for HTA reports
23 January 2019 - Citizens, patients and medical experts: selection of topics with a sense of proportion ...
Posted by Michael Wonder on 15 Jan 2019
Progressive squamous cell carcinoma of the head and neck: pembrolizumab prolongs survival
15 January 2019 - Only a few study participants were treated in compliance with the approval, therefore the extent of ...
Posted by Michael Wonder on 14 Jan 2019
Rexgenero's lead product REX-001 selected for the EUnetHTA prioritisation list for joint assessments
7 January 2019 - The Prioritisation list consists of just 14 medicinal products that have been identified as being of significant ...
Posted by Michael Wonder on 14 Jan 2019
EU Health Technology Assessment needs to move up a gear, says pressure group
9 January 2019 - The European Alliance for Personalised Medicine says it may seem to everyone that the whole debate ...
Posted by Michael Wonder on 14 Jan 2019
Mandatory or voluntary? A sticking point for European HTA
10 January 2019 - The long road to unified European Health Technology Assessment is continuing. ...
Posted by Michael Wonder on 10 Jan 2019
2018 in a nutshell: new edition with facts and graphics from the IQWiG
9 January 2019 - The focus of the 33-page brochure is information, overviews and charts on "Health Technology Assessment (HTA) ...
Posted by Michael Wonder on 17 Dec 2018
Novartis weighs reinsurance tie-up to fund ultra-expensive drugs
17 December 2018 - Could reinsures solve problem of high upfront costs of developing potentially life-saving treatments? ...
Posted by Michael Wonder on 08 Dec 2018
AMNOG as a learning system: new study on ingenol mebutate in actinic keratosis shows added benefit
3 December 2018 - Advantage over diclofenac in complete clearance of visible lesions / unclear sustainability of treatment effect ...
Posted by Michael Wonder on 07 Dec 2018
Underuse of innovative medicines in Germany: A justification for government intervention?
6 December 2018 - The German market for innovative medicines is characterised by simultaneous underuse and overuse. ...
Posted by Michael Wonder on 15 Nov 2018
German health minister calls for faster adoption of biosimilar drugs
14 November 2018 - Germany’s health minister Jens Spahn has called for faster adoption of cheaper copies of biotech drugs ...
Posted by Michael Wonder on 07 Nov 2018
Fighting for a streamlined European HTA scheme
6 November 2018 - Anyone wanting a bird’s-eye view of the political operating context for the European pharmaceutical industry need ...
Posted by Michael Wonder on 22 Oct 2018
Pharmaceutical pricing conundrum: time to get rid of it?
21 October 2018 - A basic concept of economics is that a price stems from the intersection between supply and demand ...
Posted by Michael Wonder on 20 Oct 2018
Is the EUnetHTA HTA core model fit for purpose? Evaluation from an industry perspective
18 October 2018 - The HTA Core Model was developed to improve the transferability of health technology assessment between settings. ...